Matches in Wikidata for { <http://www.wikidata.org/entity/Q94726001> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q94726001 description "clinical trial" @default.
- Q94726001 description "ensayo clínico" @default.
- Q94726001 description "ensayu clínicu" @default.
- Q94726001 description "klinisch onderzoek" @default.
- Q94726001 description "клінічне випробування" @default.
- Q94726001 description "临床试验" @default.
- Q94726001 name "TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study." @default.
- Q94726001 name "TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study." @default.
- Q94726001 type Item @default.
- Q94726001 label "TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study." @default.
- Q94726001 label "TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study." @default.
- Q94726001 prefLabel "TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study." @default.
- Q94726001 prefLabel "TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study." @default.
- Q94726001 P1132 Q94726001-952BFB00-6DBB-485B-BF13-F05EDCDEFE21 @default.
- Q94726001 P1476 Q94726001-9F5141F7-C666-4738-AB75-8F0B3C16C0A9 @default.
- Q94726001 P17 Q94726001-9A930D8C-EB20-4A07-90C7-F51CD75433C2 @default.
- Q94726001 P1813 Q94726001-524CCB9C-B3EF-4889-9C64-EFDDA2907C3E @default.
- Q94726001 P2899 Q94726001-4911F618-A279-42C3-B018-AB14A2AC32A5 @default.
- Q94726001 P3098 Q94726001-E2D6581A-2C10-4562-A694-678333881284 @default.
- Q94726001 P31 Q94726001-0D23885A-A155-4857-8231-4B4D3ED5AC6A @default.
- Q94726001 P580 Q94726001-3618CFD1-A888-4FAB-A1C2-2CB8D845C27A @default.
- Q94726001 P582 Q94726001-FE2F2215-13C3-4928-B804-B59270C72B55 @default.
- Q94726001 P6099 Q94726001-29437600-A7B3-4526-B442-B8CB8BAAB644 @default.
- Q94726001 P767 Q94726001-0AC473CE-A0BC-4D3F-9E1E-AEE79AFAF43E @default.
- Q94726001 P8005 Q94726001-2F07E44B-1F95-4679-BB7C-0AE7058E23D1 @default.
- Q94726001 P8363 Q94726001-282D17B4-56F0-4B28-9D86-8B2AFA35CA6F @default.
- Q94726001 P1132 "+202" @default.
- Q94726001 P1476 "TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study." @default.
- Q94726001 P17 Q142 @default.
- Q94726001 P1813 "TWICE-IRI" @default.
- Q94726001 P2899 "+18" @default.
- Q94726001 P3098 "NCT04392479" @default.
- Q94726001 P31 Q30612 @default.
- Q94726001 P580 "2020-09-01T00:00:00Z" @default.
- Q94726001 P582 "2021-10-01T00:00:00Z" @default.
- Q94726001 P6099 Q42824827 @default.
- Q94726001 P767 Q59536139 @default.
- Q94726001 P8005 Q76649614 @default.
- Q94726001 P8363 Q78089383 @default.